Manejo Racional de Psicofármacos en la Mujer - IGBA

More documents

Recommendations

Info

Treatment of depression by obstetriciangynecologists: a survey study. Schmidt LA. Greenberg BD Obstet Gynecol 1997 Aug;90(2):296-300. • OBJECTIVE: We performed an exploratory survey of depression diagnosis, treatment, and patient referral patterns by Fellows of ACOG. We also examined obstetrician-gynecologists' professional training in the management of clinical depression. METHODS: We sent a questionnaire to a total of 1370 ACOG Fellows. Sixty percent of the surveys were returned. RESULTS: As a group, obstetrician-gynecologists reported diagnosing an average of four new cases of depression per month. Within the overall sample, the number of new diagnoses of depression made each month was significantly greater for those defining themselves as primary care physicians than for those defining themselves as specialists. When treating depression pharmacologically, obstetrician-gynecologists reported that they overwhelmingly (74% of the time) chose selective serotonin reuptake inhibitor antidepressants. Ninety-five percent of obstetrician-gynecologists reported that they referred severely depressed patients to a mental health professional. A majority of respondents neither received residency training (80%) nor completed a continuing medical education course (60%) on the treatment of clinical depression in women. CONCLUSION: Obstetrician-gynecologists who describe themselves as primary care physicians make significantly more diagnoses of depression than those considering themselves specialists. Studies further to assess obstetrician-gynecologists' management of depression and better to define needs for professional education are warranted.
Behavioral health care integration in obstetrics and gynecology. Cassidy JM BoyleVA Med Gen Med 2003 May 14;5(2):41
Page 1: Manejo Racional de Psicofármacos e
Page 5 and 6: Continuous or intermittent dosing w
Page 7 and 8: Secuencia clínica progresiva Estr
Page 9 and 10: Relación Circular Ansiedad / Enfer
Page 11 and 12: TRASTORNOS POR ANSIEDAD. • Trasto
Page 13 and 14: Criterios fundamentales para el Epi
Page 15 and 16: DIAGNÓSTICOS DIFERENCIALES • Tra
Page 17 and 18: Comorbilidad Ansiedad \ Depresión
Page 19 and 20: Componentes Centrales del Sistema d
Page 21 and 22: Locus Coeruleus SNS Corteza prefron
Page 23 and 24: Ansiedad, Depresión y Neurogénesi
Page 25: Los puntos oscuros indican neuronas
Page 28 and 29: Estrés, Hipocampo, y Glutamato Mc
Page 30: Atrofia de neuronas hipocámpicas e
Page 35 and 36: Alteraciones estructurales en el hi
Page 37: Factores de Crecimiento Neuronal
Page 40 and 41: Farmacología Racional de los Trast
Page 42 and 43: FUNCIONES GABA • Sedante, anticon
Page 45 and 46: Clasificación de las BZD
Page 47 and 48: Método de empleo seguro • Inicio
Page 49 and 50: Efectos secundarios y Toxicidad •
Page 51: Dosis Efecto Tiempo Horas \ Días D
Page 55 and 56:
DISFUNCIÓN rCR/ HIPERACTIVIDAD CRF
Page 57 and 58:
Clasificación de los ATD • Inhib
Page 59 and 60:
Elección del ATD • Evaluación d
Page 61 and 62:
• Eficacia: Terapia con IRSS - Pr
Page 63 and 64:
El problema del ¨¨Switch¨¨ Man
Page 65 and 66:
¨¨Perlas¨¨ a tener en cuenta en
show all

Manejo Racional de Psicofármacos en la Mujer - IGBA

Create successful ePaper yourself

Delete template?

Save as template?